1 min read
Regeneron and Alnylam Win FDA Approval for Livsayis in Adults
The RNA therapeutic, identified as Livsayis (cemdisiran), was approved to treat adults with myasthenia gravis, a chronic autoimmune condition.

The Food and Drug Administration approved Livsayis (cemdisiran), a small interfering RNA therapeutic developed by Regeneron Pharmaceuticals with Alnylam Pharmaceuticals, for adults with myasthenia gravis, a chronic autoimmune condition.